Shares of Evotec SE (NASDAQ:EVO - Get Free Report) fell 3.6% on Tuesday . The company traded as low as $4.02 and last traded at $4.03. 20,210 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 54,748 shares. The stock had previously closed at $4.18.
Analyst Ratings Changes
A number of equities analysts recently weighed in on EVO shares. Jefferies Financial Group lowered shares of Evotec from a "buy" rating to a "hold" rating and lowered their price target for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of Evotec in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $5.93.
Read Our Latest Report on Evotec
Evotec Stock Performance
The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The business has a 50-day simple moving average of $4.63 and a 200-day simple moving average of $4.12.
Institutional Trading of Evotec
Several hedge funds have recently added to or reduced their stakes in the company. Novo Holdings A S purchased a new stake in Evotec during the second quarter worth approximately $71,183,000. Wellington Management Group LLP lifted its position in shares of Evotec by 29.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after buying an additional 602,858 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Evotec in the 3rd quarter valued at $512,000. DCF Advisers LLC grew its position in shares of Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after buying an additional 67,156 shares during the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new stake in Evotec during the 3rd quarter worth $104,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
